interaction records 54 assistance programs 55 0 personal data stored
OmniRx › Tools › Generic competition check › Vosoritide

Generic competition · all medicines · read 12 November 2026

Is there a generic of Vosoritide, and who makes it?

Vosoritide appears in 1 dosage-form group in the FDA Orange Book as of 12 November 2026, with no generic maker listed as marketed. 1 group has a brand listed as marketed and no generic listed as marketed. The data does not state why, and it does not state that one is coming. This is the Orange Book's listing, not a forecast.

Compiled and checked by Vincent Wesley Couey (ORCID 0009-0005-6869-308X) from the Orange Book data files, downloaded 12 November 2026.

Not medical advice. This page reports what the FDA's Orange Book lists, not what a pharmacy has in stock, what anything costs, or whether a generic is right for you. Ask your pharmacist or prescriber about your own medicine.
Vosoritide1 dosage-form group in the Orange Book
0generic makers listed
  1. Vosoritide appears in 1 dosage-form group in the FDA Orange Book as of 12 November 2026, with no generic maker listed as marketed.
  2. 1 group has a brand listed as marketed and no generic listed as marketed. The data does not state why, and it does not state that one is coming.
  3. Patents and exclusivities are shown as listed by the application holder; the Orange Book does not rule on them, and a listed patent is not a statement that a generic is blocked. This says nothing about price, supply or quality.

Powder, Subcutaneous

Brand listed, no generic listed as marketed

Brand listed as marketed: Voxzogo. No generic is listed as marketed.

20202025203020352040204501brand 2021data datePatent RE48267 listed to expire 20 May 2030Patent 8198242 listed to expire 11 June 2035Patent 11911446 listed to expire 1 August 2036Patent 11590204 listed to expire 1 August 2036Patent 12514906 listed to expire 1 August 2036Patent 10646550 listed to expire 1 August 2036Patent 9907834 listed to expire 1 August 2036Patent 12233106 listed to expire 11 July 2042Exclusivity NCE to 19 November 2026Exclusivity ODE-387 to 19 November 2028Exclusivity ODE-449 to 20 October 2030
generic makers listed as marketed, by first approvallisted patent expiryexclusivity end

Patents and exclusivities still listed

  • 19 November 2026Exclusivity NCE Voxzogo
  • 19 November 2028Exclusivity ODE-387 Voxzogo
  • 20 October 2030Exclusivity ODE-449 Voxzogo
  • 20 May 2030Patent RE48267
  • 11 June 2035Patent 8198242 drug substance
  • 1 August 2036Patent 11911446
  • 1 August 2036Patent 11590204 drug product
  • 1 August 2036Patent 12514906 drug product
  • 1 August 2036Patent 10646550 drug product
  • 1 August 2036Patent 9907834 drug product
  • 11 July 2042Patent 12233106

US Food and Drug Administration, Orange Book data files, downloaded 12 November 2026. A listed patent is not a ruling that a generic is blocked, and no figure here says anything about price, supply or quality. Check the Orange Book.

Where can you go from this result?

Open it in the check to search another medicine, or see every brand with no generic listed. The FDA explains generic approval in how generic drugs are approved and the FDA generic drug facts, and the Orange Book itself is the FDA Orange Book. To check what is available now, ask your pharmacist, and see the FDA drug shortages page.